Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-11	SEK 33.40	+3.09%	10,691
26-09-10	SEK 32.40	+9.09%	29,108
26-09-09	SEK 29.70	-1.33%	6,875
26-09-08	SEK 30.10	-0.99%	3,110
26-09-07	SEK 30.40	-2.88%	5,824

Delayed Quote Nasdaq Stockholm

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 12:00:00 2026-09-11 EDT			5-day change	1st Jan Change
33.40 ^SEK	+3.09%		+6.71%	+234.00%

08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	Fluicell increases revenue and turns to operating profit	FW

Market Cap	45.88M 4.74M 4.08M 3.86M 3.5M 6.57M 452M 6.6M 17.64M 230M 17.78M 17.39M 727M	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	43.62M 4.5M 3.88M 3.67M 3.33M 6.25M 430M 6.28M 16.77M 219M 16.91M 16.54M 691M	EV / Sales 2024	0.71x	EV / Sales 2025	0.75x
Free-Float	81.23%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	FLUI	Delayed
Deutsche Boerse AG	5J90	Delayed
Boerse Muenchen	5J90	Real-time
Börse Stuttgart	5J90	Delayed

08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	Fluicell increases revenue and turns to operating profit	FW
05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE
05-08	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Fluicell nominates AstraZeneca executive to Board of Directors	FW
04-30	Committee proposes Niklas Frisk as Fluicell chairman	RE
04-30	Fluicell proposes new Board of Directors	FW
02-20	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
02-20	Fluicell Q4 net sales SEK 3.8 mln	RE
02-20	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Fluicell gets EPO approval for microfluidics patent	RE
02-11	Fluicell Granted EU Patent for Microfluidics Technology	FW

Fluicell AB Stock

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation : Fluicell AB

Chart: Fluicell AB

Latest news : Fluicell AB

Press Releases : Fluicell AB

Quotes and Performance

Price Extremes

Managers and Directors : Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

25-09-02	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
25-08-22	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
21-09-29	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
21-07-01	BioStock: 2021 represents beginning of new era for Fluicell	AQ
21-05-18	BioStock: Fluicell dives into regenerative medicine field	AQ

1 day	+3.09%
1 week	+6.71%
Current month	+10.96%
1 month	+14.38%
3 months	-13.92%
6 months	+203.64%
Current year	+234.00%

1 week	28.4	34.1
1 month	28.3	43
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	594.3
5 years	7.45	12,145
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	2022-12-31
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	2016-12-31
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	2023-06-30

Director	Title	Age	Since
Jan Orwar BRD	Director/Board Member	62	2014-12-31
Daniel T. Chiu BRD	Director/Board Member	54	2016-12-31
Niklas Frisk CHM	Chairman	51	2026-06-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	+3.09%	+6.71%	+151.13%	-92.05%	4.74M
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.37%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+520.30%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.85%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+73.19%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+108.58%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+30.20%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+36.66%	13.28B
Average	+0.75%	-2.21%	+72.67%	+82.99%	26.48B
Weighted average by Cap.	+0.41%	-3.50%	+74.57%	+124.86%

	2024	2025
Net sales	5.35M 552K 476K 450K 408K 766K 52.74M 770K 2.06M 26.83M 2.07M 2.03M 84.79M	15.22M 1.57M 1.35M 1.28M 1.16M 2.18M 150M 2.19M 5.85M 76.35M 5.9M 5.77M 241M
Net income	-15.51M -1.6M -1.38M -1.31M -1.18M -2.22M -153M -2.23M -5.96M -77.81M -6.01M -5.88M -246M	-8.33M -860K -741K -702K -636K -1.19M -82.15M -1.2M -3.2M -41.8M -3.23M -3.16M -132M
Net Debt	-15.92M -1.64M -1.42M -1.34M -1.22M -2.28M -157M -2.29M -6.12M -79.88M -6.17M -6.04M -252M	-2.26M -233K -201K -190K -173K -324K -22.3M -326K -870K -11.35M -877K -858K -35.85M